MX2018006225A - Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). - Google Patents

Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).

Info

Publication number
MX2018006225A
MX2018006225A MX2018006225A MX2018006225A MX2018006225A MX 2018006225 A MX2018006225 A MX 2018006225A MX 2018006225 A MX2018006225 A MX 2018006225A MX 2018006225 A MX2018006225 A MX 2018006225A MX 2018006225 A MX2018006225 A MX 2018006225A
Authority
MX
Mexico
Prior art keywords
nash
prophylaxis
treatment
indicates
pharmaceutical composition
Prior art date
Application number
MX2018006225A
Other languages
English (en)
Inventor
Shigeru Ushiyama
Eiji Okanari
Hirofumi Matsunaga
Kenji Nishikawa
Shinohara Yuuko
Nonouchi Shinpei
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of MX2018006225A publication Critical patent/MX2018006225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms

Abstract

La presente invención proporciona el uso farmacéutico de antagonistas LPA1, por ejemplo, compuestos de tiofeno halogenado- a que tienen una estructura específica o sales farmacológicamente aceptables de los mismos, como fármacos para el tratamiento y/o prevención de NASH; una composición farmacéutica para el tratamiento y/o prevención de NASH incluye, como un ingrediente activo, un antagonista LPA1, por ejemplo, un compuesto representado por la fórmula general (I): (ver Fórmula) [en donde R1 es un átomo de hidrógeno o un grupo metoxi; R2 es un átomo de hidrógeno o un grupo alquilo de C1-C6; X es un átomo de halógeno; y A es un grupo seleccionado del grupo que consiste en los grupos: (ver Fórmula) o una sal farmacológicamente aceptable de los mismos.
MX2018006225A 2015-11-20 2016-11-18 Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash). MX2018006225A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015227468 2015-11-20
JP2016111944 2016-06-03
PCT/JP2016/084227 WO2017086430A1 (ja) 2015-11-20 2016-11-18 Ｎａｓｈの治療又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
MX2018006225A true MX2018006225A (es) 2018-11-09

Family

ID=58717447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006225A MX2018006225A (es) 2015-11-20 2016-11-18 Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).

Country Status (11)

Country Link
US (1) US20180360803A1 (es)
EP (1) EP3378491A4 (es)
JP (1) JPWO2017086430A1 (es)
KR (1) KR20180082564A (es)
CN (1) CN108348610A (es)
AU (1) AU2016355863A1 (es)
BR (1) BR112018010107A8 (es)
CA (1) CA3005811A1 (es)
MX (1) MX2018006225A (es)
RU (1) RU2018122224A (es)
WO (1) WO2017086430A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953472C (en) * 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
WO2019041340A1 (en) 2017-09-04 2019-03-07 Eli Lilly And Company LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
CA3158743A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
CN107721940A (zh) * 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
AU2013366898B2 (en) * 2012-12-28 2017-06-29 Ube Corporation Halogen-substituted heterocyclic compound
MX2015013303A (es) * 2013-03-15 2015-12-15 Epigen Biosciences Inc Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
CA2953472C (en) * 2014-06-27 2022-08-02 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt

Also Published As

Publication number Publication date
JPWO2017086430A1 (ja) 2018-09-06
BR112018010107A2 (pt) 2018-11-21
EP3378491A1 (en) 2018-09-26
AU2016355863A1 (en) 2018-07-05
RU2018122224A (ru) 2019-12-25
CN108348610A (zh) 2018-07-31
RU2018122224A3 (es) 2020-03-27
CA3005811A1 (en) 2017-05-26
KR20180082564A (ko) 2018-07-18
WO2017086430A1 (ja) 2017-05-26
BR112018010107A8 (pt) 2023-05-09
EP3378491A4 (en) 2019-07-17
US20180360803A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
PH12017501326A1 (en) Tgf-� inhibitors
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
PH12018500065A1 (en) Oxysterols and methods of use thereof
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
EP4316591A3 (en) Oxysterols and methods of use thereof
MD20160012A2 (ro) Formulare de inhibitori SYK
MX2017013678A (es) Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende.
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
MX2019006843A (es) Inhibidor de cdk4/6.
PH12018500378A1 (en) Novel annelated phenoxyacetamides
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
PH12015501696B1 (en) Prophylactic or therapeutic drug for constipation
NZ630795A (en) Crystalline form of vsn16